|
The main company, Everlight
has successfully commercialized several active
pharmaceutical ingredients (APIs) . Utilizing enzymatic
resolution technology for optically active compound
purification and delicate instrumentation for impurity
assays, we have entered the field of biopharmaceuticals by
introducing therapeutically important prostagladins and
cardiovascular drugs to the market. , Everlight's future
strategy will focus upon the development of
biopharmaceutical processes for making these drug
substances.
In
clinic applications, prostaglandins have a wide range of
therapeutic uses with impressive results of treatment,
especially for the recovery of various cardiovascular
diseases. As to the calcium channel blocker (Felodipine)
and the ACE inhibitor (Enalapril), they are among the few
best ones recognized by the medical community for treatment
of hypertensives in today's healthcare market.
In
manufacturing , Everlight's newly completed facility has
implemented the cGMP system. Our quality policy is in
conformance with the universal ICH guidance. In the future,
ECI will continue to commercialize more pharmaceutial
products to meet the growing market demand and to contribute
to the human well-being.
|
|
Products
|
Applications
|
|
Prostaglandins
|
|
|
Alprostadil (PG E1)
|
Treatment of cardiovascular diseases.
|
|
Misoprostol
|
Treatment of peptic and duodenal ulcers caused by use of
NSAIDs
|
|
Cloprostenol Sodium
|
Labor induction and breeding management in veterinary
|
|
Dinoprostone (PG
E2)
|
Labor induction
|
|
Latanoprost
|
Treatment of glaucoma (ocular
pressure)
|
|
Cardiovascular drugs
|
|
|
Felodipine
|
Anti-hypertensive
|
|
Intermediates
NEPA/NEPA-NCA
|
Intermediates for making ACE inhibitors
|
|
|
(Please contact us should you require more detailed
information about the products) |
